Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? Insights into valvular pathology

References

• Freeman RV, Otto CM. Spectrum of calcific aortic valve disease. Pathogenesis, disease progression, and treatment strategies. Circulation111, 3316–3326 (2005).
   PubMed Web of Science ®Google Scholar
• Baumgartner H. Aortic stenosis: medical and surgical management. Heart91, 1483–1488 (2005).
   PubMed Web of Science ®Google Scholar
• Faggiano P, Antonini-Canterin F, Erlicher A et al. Progression of aortic valve sclerosis to aortic stenosis. Am. J. Cardiol.91, 99–101 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Maurer G, Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis. Eur. Heart J.23, 1417–1421 (2002).
   PubMed Web of Science ®Google Scholar
• Bonow RO, Chatterjee K, de Leon AC et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease. J. Am. Coll. Cardiol.48, e1–e148 (2006).
   Google Scholar
• Iung B, Gohlke-Bärwolf, Tornos P et al.; on behalf of the Working Group on Valvular Heart Disease. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur. Heart J.23, 1253–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside – emerging clinical and cellular concepts. Heart89, 801–805 (2003).
   PubMed Web of Science ®Google Scholar
• Mohler ER III. Mechanisms of aortic valve calcification. Am. J. Cardiol.94, 1396–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation101, 2497–2502 (2000).
   PubMed Web of Science ®Google Scholar
• Otto CM, Lind BK, Kitzman DW et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med.341, 142–147 (1999).
   PubMed Web of Science ®Google Scholar
• Rahimtoola SH. The year in valvular heart disease. J. Am. Coll. Cardiol.47, 427–439 (2006).
   PubMedGoogle Scholar
• Chan KL. Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol.42, 593–599 (2003).
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation110, 1180–1182 (2004).
   PubMed Web of Science ®Google Scholar
• Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesions of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation90, 844–853 (1994).
   PubMed Web of Science ®Google Scholar
• Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenquist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol.23, 1162–1170 (1994).
   PubMedGoogle Scholar
• Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation103, 1522–1528 (2001).
   PubMed Web of Science ®Google Scholar
• Wallby L, Janerot-Sjöberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart88, 348–351 (2002).
   PubMed Web of Science ®Google Scholar
• Skowasch D, Schrempf S, Lentini S et al. Presence of Chlamydia pneumoniae and cytomegalovirus in degenerated aortic valves. Z. Kardiol.91, 290–296 (2002).
   PubMedGoogle Scholar
• Skowasch D, Yeghiazaryan K, Schrempf S et al. Persistence of Chlamydia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues. J. Heart Valve Dis.12, 68–75 (2003).
   PubMed Web of Science ®Google Scholar
• Skowasch D, Schrempf S, Wernert N et al. Cells of primarily nonvalvular origin in degenerative aortic valve stenosis and bioprostheses. Eur. Heart J.26, 2576–2580 (2005).
   PubMed Web of Science ®Google Scholar
• Kuusisto J, Räsänen K, Särkioja E, Alarakkola E, Kosma VM. Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart91, 576–582 (2005).
   PubMedGoogle Scholar
• Santin M, Colombo P, Bruschi G. Interfacial biology of in-stent restenosis. Expert Rev. Med. Devices2(4), 429–443 (2005).
   PubMed Web of Science ®Google Scholar
• Skowasch D, Jabs A, Andrié R, Dinkelbach S, Lüderitz B, Bauriedel G. Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc. Res.60, 684–691 (2003).
   PubMed Web of Science ®Google Scholar
• Bauriedel G, Jabs A, Skowasch D et al. Dendritic cells in neointima formation after rat carotid balloon injury. Coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. J. Am. Coll. Cardiol.42, 930–938 (2003).
   PubMedGoogle Scholar
• Skowasch D, Jabs A, Andrié R et al. Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis. J. Vasc. Res.41, 525–534 (2004).
   PubMed Web of Science ®Google Scholar
• Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg.75, 457–465 (2003).
   PubMed Web of Science ®Google Scholar
• Kaden JJ, Dempfle CE, Grobholz R et al. Inflammatory regulation of extracellular matrix remodelling in calcific aortic valve stenosis. Cardiovasc. Pathol.14, 80–87 (2005).
   PubMed Web of Science ®Google Scholar
• Kaden JJ, Dempfle CE, Grobholz R et al. Interleukin-1β promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis170, 205–211 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol.16, 523–532 (1996).
   PubMed Web of Science ®Google Scholar
• Jian B, Jones PL, Quanyi L, Mohler ER III, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am. J. Pathol.159, 321–327 (2001).
   PubMedGoogle Scholar
• Satta J, Melkko J, Pollanen R et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J. Am. Coll. Cardiol.39, 96–101 (2002).
   PubMed Web of Science ®Google Scholar
• Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc. Pathol.9, 281–286 (2000).
   PubMed Web of Science ®Google Scholar
• Mazzone A, Epistolato MC, De Caterina R et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J. Am. Coll. Cardiol.43, 1670–1674 (2004).
   PubMed Web of Science ®Google Scholar
• Galante A, Pietroiusti A, Vellini M et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J. Am. Coll. Cardiol.38, 1078–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez PD, Santos JL, Kaski JC et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am. J. Cardiol.97, 90–93 (2006).
   PubMedGoogle Scholar
• Gerber IL, Stewart RA, Hammett CJ et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am. J. Cardiol.92, 1129–1132 (2003).
   PubMed Web of Science ®Google Scholar
• Skowasch D, Schrempf S, Preusse CJ et al. Tissue resident C reactive protein within degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart92, 495–498 (2006).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol.158, 1039–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Glader CA, Birgander LS, Söderberg S et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur. Heart J.24, 198–208 (2003).
   PubMed Web of Science ®Google Scholar
• Juvonen J, Laurila A, Juvonen T et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol.29, 1054–1059 (1997).
   PubMed Web of Science ®Google Scholar
• Juvonen J, Juvonen T, Laurila A et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann. Intern. Med.128, 741–744 (1998).
   PubMedGoogle Scholar
• Kaden JJ, Bickelhaupt S, Grobholz R et al. Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis: immunohistochemistry study and review of the literature. J. Heart Valve Dis.12, 447–453 (2003).
   PubMedGoogle Scholar
• Radke PW, Ortlepp JR, Merkelbach-Bruse S et al. Prevalence of cytomegalovirus in nonrheumatic stenotic aortic valves. Am. J. Cardiol.89, 477–479 (2002).
   PubMedGoogle Scholar
• Rajamannan NM, Subramaniam M, Stock SR et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart91, 806–810 (2005).
   PubMed Web of Science ®Google Scholar
• Olsson M, Thyberg J, Nilson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol.19, 1218–1222 (1999).
   PubMed Web of Science ®Google Scholar
• Sun Y, Diaz-Arias AA, Weber KT. Angiotensin-converting enzyme, bradykinin, and angiotensin II receptor binding in rat skin, tendon, and heart valves: an in vitro, quantitative autoradiographic study. J. Lab. Clin. Med.123, 372–377 (1994).
   PubMedGoogle Scholar
• O’Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation106, 2224–2230 (2002).
   PubMed Web of Science ®Google Scholar
• Mohler ER, Adam LP, McCelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler. Thromb. Vasc. Biol.17, 547–552 (1997).
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation92, 2163–2168 (1995).
   PubMed Web of Science ®Google Scholar
• Kim KM. Apoptosis and calcification. Scanning Microsp.9, 1137–1175 (1995).
   PubMedGoogle Scholar
• Caira FC, Stock SR, Gleason TG et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol.47, 1707–1712 (2006).
   PubMed Web of Science ®Google Scholar
• Millonig G, Niederegger H, Rabl W et al. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler. Thromb. Vasc. Biol.21, 503–508 (2001).
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med.353, 999–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Visconti RP, Ebihara Y, LaRue AC et al. An in vivo analysis of hematopoietic stem cell potential. Hematopoietic origin of cardiac valve interstitial cells. Circ. Res.98, 690–696 (2006).
   PubMed Web of Science ®Google Scholar
• Liebe V, Brueckmann M, Borggrefe M, Kaden JJ. Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J.27, 773–778 (2006).
   PubMedGoogle Scholar
• O’Brien KD, Probstfield J, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Intern. Med.165, 858–862 (2005).
   PubMedGoogle Scholar
• Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation104, 2205–2209 (2001).
   PubMed Web of Science ®Google Scholar
• Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol.40, 1723–1730 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation110, 1291–1295 (2004).
   PubMed Web of Science ®Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med.352, 2441–2443 (2005).
   PubMedGoogle Scholar
• Olsen MH, Wachtell K, Bella JN et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am. J. Cardiol.94, 1076–1080 (2004).
   PubMedGoogle Scholar
• Lindblom D, Lindblom U, Qvist J, Lundstrom H. Long-term relative survival rates after heart valve replacement. J. Am. Coll. Cardiol.15, 566–573 (1990).
   PubMed Web of Science ®Google Scholar
• Jamieson SW, Madani MM. The choice of valve protheses. J. Am. Coll. Cardiol.44, 389–390 (2004).
   PubMedGoogle Scholar
• Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann. Thorac. Surg.79, 1072–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Butany J, Leask R. The failure modes of biological prosthetic heart valves. J. Long Term Eff. Med. Implants11, 115–135 (2001).
   PubMedGoogle Scholar
• Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomised trial. J. Am. Coll. Cardiol.36, 1152–1158 (2000).
   PubMed Web of Science ®Google Scholar
• Nollert G, Miksch J, Kreuzer E, Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J. Thorac. Cardiovasc. Surg.126, 965–968 (2003).
   PubMedGoogle Scholar
• Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J. Thorac. Cardiovasc. Surg.126, 969–976 (2003).
   PubMed Web of Science ®Google Scholar
• Human P, Zilla P. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration? J. Long Term Eff. Med. Implants11, 199–220 (2001).
   PubMedGoogle Scholar
• Antonini-Canterin F, Zuppiroli A, Popescu BA et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am. J. Cardiol.92, 1479–1482 (2003).
   PubMed Web of Science ®Google Scholar
• Wilhelmi M, Fischer S, Mertsching H, Leyh R, Karck M, Haverich A. Is chronic graft rejection the reason for degenerative changes in allogeneic and xenogeneic heart valve prostheses: immunohistochemical evaluation of inflammatory factors. Z. Kardiol.91, 825–832 (2002).
   PubMedGoogle Scholar
• Shimizaki Y, Kuraoka S, Takeda F, Watanabe T, Inui K. Mitral valve re-replacement for impaired bioprosthesis after 19 years in a patient undergoing steroid treatment. J. Heart Valve Dis.12, 45–47 (2003).
   PubMed Web of Science ®Google Scholar
• Eishi K, Ishibashi-Ueda H, Nakano K et al. Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy. J. Heart Valve Dis.5, 668–672 (1996).
   PubMed Web of Science ®Google Scholar
• Liao K, Frater RW, LaPietra A, Ciuffo G, Llardi CF, Seifter E. Time-dependent effect of glutaraldehyde on the tendency to calcify of both autografts and xenografts. Ann. Thorac. Surg.60(Suppl.), S343–S347 (1995).
   Google Scholar
• Zilla P, Bezuidenhout D, Weissenstein C, van der Walt A, Human P. Diamine extension of glutaraldehyde crosslinks mitigates bioprosthetic aortic wall calcification in the sheep model. J. Biomed. Mater. Res.56, 56–64 (2001).
   PubMed Web of Science ®Google Scholar
• Grabenwoger M, Sider J, Fitzal F et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. Ann. Thorac. Surg.62, 772–777 (1996).
   PubMedGoogle Scholar
• Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular and valvar calcification: recent advances. Heart85, 13–17 (2001).
   PubMed Web of Science ®Google Scholar
• Srivatsa SS, Harrity PJ, Maercklein PB et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J. Clin. Invest.99, 996–1009 (1997).
   PubMed Web of Science ®Google Scholar
• Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ. Res.96, 717–722 (2005).
   PubMed Web of Science ®Google Scholar
• Shen M, Kara-Mostefa A, Chen L et al. Effect of ethanol and ether in the prevention of calcification of bioprostheses. Ann. Thorac. Surg.71(Suppl.), S413–S416 (2001).
   Google Scholar
• Ogle MF, Kelly SJ, Bianco RW, Levy RJ. Calcification resistance with aluminium-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. Ann. Thorac. Surg.75, 1267–1273 (2003).
   PubMed Web of Science ®Google Scholar
• Kim KM. Cells, rather than extracellular matrix, nucleate apatite in glutaraldehyde-treated vascular tissue. J. Biomed. Mater. Res.59, 639–645 (2002).
   PubMed Web of Science ®Google Scholar
• Gao G, Wu YX, Grunkemeier GL, Furnary AP, Starr A. Durability of pericardial versus porcine aortic valves. J. Am. Coll. Cardiol.44, 384–388 (2004).
   PubMed Web of Science ®Google Scholar
• Clark JN, Ogle MF, Ashworth P, Bianco RW, Levy RJ. Prevention of calcification of bioprosthetic heart valve cusp and aortic wall with ethanol and aluminium chloride. Ann. Thorac. Surg.79, 897–904 (2005).
   PubMed Web of Science ®Google Scholar
• Sutherland FW, Perry TE, Yu Y et al. From stem cells to viable autologous semilunar heart valve. Circulation111, 2783–2791 (2005).
   PubMed Web of Science ®Google Scholar
• Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation106, 3006–3008 (2002).
   PubMed Web of Science ®Google Scholar
• Feldman T. Percutaneous valve repair and replacement. Challenges encountered, challenges met, challenges ahead. Circulation113, 771–773 (2006).
   PubMed Web of Science ®Google Scholar
• Shemin RJ. Percutaneous valve intervention. A surgeon’s perspective. Circulation113, 774–775 (2006).
   PubMedGoogle Scholar